WO2018156649A1 - Compositions de molécules de modulateur cellules t (tcm) et utilisation connexe - Google Patents

Compositions de molécules de modulateur cellules t (tcm) et utilisation connexe Download PDF

Info

Publication number
WO2018156649A1
WO2018156649A1 PCT/US2018/019044 US2018019044W WO2018156649A1 WO 2018156649 A1 WO2018156649 A1 WO 2018156649A1 US 2018019044 W US2018019044 W US 2018019044W WO 2018156649 A1 WO2018156649 A1 WO 2018156649A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
tcm
composition
previous
cell
Prior art date
Application number
PCT/US2018/019044
Other languages
English (en)
Inventor
David Arthur Berry
Douglas Ewen Cameron
Brett Blackman
Chantal KUHN
Original Assignee
Flagship Pioneering, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering, Inc. filed Critical Flagship Pioneering, Inc.
Publication of WO2018156649A1 publication Critical patent/WO2018156649A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des molécules de modulateur de cellules T et des compositions pharmaceutiques qui ont des caractéristiques bénéfiques appropriées pour une administration à un tissu ou à une cellule cible (par exemple, ex vivo ou in vivo), utiles dans des procédés pour modifier (par exemple, modifier l'activation ou l'inhibition de) une voie de signalisation cible dans un tissu ou une cellule (par exemple, ex vivo ou in vivo), et/ou pour traiter un sujet (par exemple, un mammifère tel qu'un être humain). Les préparations et les compositions de l'invention peuvent également être modifiées, par exemple, des variants, des fusions ou des combinaisons.
PCT/US2018/019044 2017-02-22 2018-02-21 Compositions de molécules de modulateur cellules t (tcm) et utilisation connexe WO2018156649A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462009P 2017-02-22 2017-02-22
US62/462,009 2017-02-22

Publications (1)

Publication Number Publication Date
WO2018156649A1 true WO2018156649A1 (fr) 2018-08-30

Family

ID=63254061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/019044 WO2018156649A1 (fr) 2017-02-22 2018-02-21 Compositions de molécules de modulateur cellules t (tcm) et utilisation connexe

Country Status (1)

Country Link
WO (1) WO2018156649A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
WO2020009938A1 (fr) * 2018-07-03 2020-01-09 Catalent Pharma Solutions, Llc Molécules protéiques multifonctionnelles comprenant de la décorine et utilisation associée
US20200101016A1 (en) * 2018-10-02 2020-04-02 Exosome Therapeutics, Inc. Compositions and methods for producing exosome loaded therapeutics for treating cardiovascular disease
WO2020077190A1 (fr) * 2018-10-12 2020-04-16 Jumaa Weinacht Hassan Anticorps monoclonal pour le traitement de la leucémie lymphoblastique aiguë
WO2021209402A3 (fr) * 2020-04-15 2021-12-02 F. Hoffmann-La Roche Ag Immunoconjugués
CN114432441A (zh) * 2022-01-11 2022-05-06 中国人民解放军陆军军医大学第一附属医院 一种pd-1修饰的金复合硒化铜纳米粒子及其在介导光热靶向治疗癌症方面的应用
US11629195B2 (en) 2019-02-01 2023-04-18 Regeneron Pharmaceuticals, Inc. Anti-IL2 receptor gamma antigen-binding proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249701A1 (en) * 2002-08-08 2005-11-10 Morre Michel C Il-7 Drug substance, composition, preparation and uses
US20100015132A1 (en) * 2003-07-18 2010-01-21 Schering Corporation Uses of mammalian cytokines and agonists; related reagents
WO2010085643A1 (fr) * 2009-01-22 2010-07-29 University Of Miami Ciblage de la signalisation il-7 à des fins de traitement de la sclérose en plaques et d'autres troubles dépendant de la signalisation il-7
US20110206698A1 (en) * 2010-02-24 2011-08-25 Rinat Neuroscience Corporation Antagonist anti-il-7 receptor antibodies and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249701A1 (en) * 2002-08-08 2005-11-10 Morre Michel C Il-7 Drug substance, composition, preparation and uses
US20100015132A1 (en) * 2003-07-18 2010-01-21 Schering Corporation Uses of mammalian cytokines and agonists; related reagents
WO2010085643A1 (fr) * 2009-01-22 2010-07-29 University Of Miami Ciblage de la signalisation il-7 à des fins de traitement de la sclérose en plaques et d'autres troubles dépendant de la signalisation il-7
US20110206698A1 (en) * 2010-02-24 2011-08-25 Rinat Neuroscience Corporation Antagonist anti-il-7 receptor antibodies and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COSENZA ET AL.: "Comparative model building of interleukin-7 using interleukin-4 as a template: A structural hypothesis that displays atypical surface chemistry in helix D important for receptor activation", PROTEIN SCIENCE, vol. 9, no. 5, May 2000 (2000-05-01), pages 916 - 926, XP055539734, Retrieved from the Internet <URL:DOI:10.1110/ps.9.5.916> *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
WO2020009938A1 (fr) * 2018-07-03 2020-01-09 Catalent Pharma Solutions, Llc Molécules protéiques multifonctionnelles comprenant de la décorine et utilisation associée
US11377488B2 (en) 2018-07-03 2022-07-05 Catalent Pharma Solutions, Llc Multifunctional protein molecules comprising decorin and use thereof
US11879009B2 (en) 2018-07-03 2024-01-23 Catalent Pharma Solutions, Llc Multifunctional protein molecules comprising decorin and use thereof
US20200101016A1 (en) * 2018-10-02 2020-04-02 Exosome Therapeutics, Inc. Compositions and methods for producing exosome loaded therapeutics for treating cardiovascular disease
WO2020077190A1 (fr) * 2018-10-12 2020-04-16 Jumaa Weinacht Hassan Anticorps monoclonal pour le traitement de la leucémie lymphoblastique aiguë
US11629195B2 (en) 2019-02-01 2023-04-18 Regeneron Pharmaceuticals, Inc. Anti-IL2 receptor gamma antigen-binding proteins
WO2021209402A3 (fr) * 2020-04-15 2021-12-02 F. Hoffmann-La Roche Ag Immunoconjugués
CN114432441A (zh) * 2022-01-11 2022-05-06 中国人民解放军陆军军医大学第一附属医院 一种pd-1修饰的金复合硒化铜纳米粒子及其在介导光热靶向治疗癌症方面的应用
CN114432441B (zh) * 2022-01-11 2023-04-25 中国人民解放军陆军军医大学第一附属医院 一种pd-1修饰的金复合硒化铜纳米粒子及其在介导光热靶向治疗癌症方面的应用

Similar Documents

Publication Publication Date Title
WO2018156649A1 (fr) Compositions de molécules de modulateur cellules t (tcm) et utilisation connexe
JP7062647B2 (ja) Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
JP7055794B2 (ja) クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体
CN110267982B (zh) 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
JP6912386B2 (ja) 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
CN105829349B (zh) 肽嵌合抗原受体t细胞开关和其用途
RU2764031C2 (ru) Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью
JP2021040641A (ja) クローディンを発現するガン疾患を処置するための剤
JP6041799B2 (ja) Ｔｒａｉｌｒ２特異的多量体足場
KR20170044115A (ko) 동일한 진핵생물 세포 생산 숙주 내 조건부 활성 생체 단백질의 발견 및 제조
KR20190039085A (ko) 세포의 고갈을 위한 조성물 및 방법
KR20190107097A (ko) Cd137+ 세포의 고갈을 위한 조성물 및 방법
JP2023516388A (ja) 抗ｃｃｒ８剤
US20220010337A1 (en) Targeted active gene editing agent and methods of use
CN107580603A (zh) 条件活性生物蛋白
CN114340681A (zh) 巨噬细胞特异性接合器组合物及其使用方法
EA028178B1 (ru) Улучшенные связывающие сывороточный альбумин варианты
JP2022512629A (ja) Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
WO2023020621A1 (fr) Anticorps anti-ccr8 et leurs utilisations
JP2021504412A (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
CN112566671A (zh) 使用抗体药物缀合物(adc)的治疗方法
WO2019195179A1 (fr) Compositions et méthodes pour le traitement de maladies inflammatoires
JP5593231B2 (ja) ヒトｃｄ１５４−結合性の合成ペプチドおよびその使用
CA3158235A1 (fr) Anticorps monoclonal anti-b7-h3 et ses procedes d&#39;utilisation
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18757754

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18757754

Country of ref document: EP

Kind code of ref document: A1